Related Experiment Video
Updated: Jan 14, 2026

Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
Risk model derivation and clinical outcomes in COVID-19 pneumonia patients discharged from the emergency department
Francisco Javier Martín-Sánchez1,2,3, Sara Laínez-Martínez4, Pedro López-Ayala5
1Hospital Emergencias Isabel Zendal, Madrid, Spain.
Objectives:
To develop and validate a clinical model to predict 30-day mortality in high-risk COVID-19 patients evaluated in the Emergency Department, and to evaluate outcomes in adults with COVID-19 pneumonia classified as low-risk by the model and discharged home.
Methods:
Secondary analysis of the COVID-19\_URG-HCSC registry at Hospital Clínico San Carlos (Madrid). Phase 1 (Feb-Apr 2020): derivation of a model in patients aged ≥18 years with probable or confirmed COVID-19 who were classified as high-risk at triage (age ≥55 years, baseline oxygen saturation <96% on arrival, or pulmonary infiltrates on chest radiograph). The primary outcome was 30-day all-cause mortality. Phase 2 (Sep 2020-May 2021): validation in adults with low-risk pneumonia discharged home and monitored by telephone. Primary outcomes were 30-day all-cause mortality, revisits, and hospitalization.
Results:
Of 2,436 eligible patients in phase 1, age, oxygen saturation, renal function, LDH, CRP, platelet count and dementia were independent mortality predictors. The model showed excellent discrimination (AUC 0.918) and good calibration, and was implemented in a web-based tool. In phase 2, 565 patients with low-risk pneumonia were monitored; no deaths occurred at 30 days. Re-attendance was 8.0% and hospitalisation 12.6%, mainly for respiratory failure. All hospitalised patients were ultimately discharged home.
Conclusions:
The PrediCOVID model provides accurate risk stratification and, when combined with telemonitoring, enables safe early discharges while reducing hospital burden.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Related Concept Videos
Pneumonia III: Complications and Assessment
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: